SLU-PP-332
Also known as: ERR agonist, Exercise-mimetic small molecule
SLU-PP-332 (also called ERR agonist or Exercise-mimetic small molecule) is an ERR agonist. SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, orphan nuclear receptors that act as transcriptional regulators of oxidative metabolism.
For research use only.
Key Facts
- CAS
- 303760-60-3
- Molecular Weight (MW)
- 467.5 g/mol
- Half-life
- Not established
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Sep 6, 2026
- Reviewed
- Aug 30, 2026
- Targets
- ERRαERRβERRγ
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 18
- Listed offers
- 38
- Median price per mg
- $225.00/mg
- Typical $106.36–$314.99/mg
Research summary
Pan-estrogen-related-receptor agonist studied as an exercise mimetic in mice (2023). Not a peptide and not FDA-approved.
Peptide Library's SLU-PP-332 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
SLU-PP-332 dosage: no established human dose
SLU-PP-332 has no established human dosage. No trial is registered and no human study is indexed; it entered the literature in 2023 and everything published about it is preclinical. The mouse dosing is well characterised and specific: 50 mg/kg by intraperitoneal injection twice daily, for periods of 7 to 28 days. That is an injected rodent dose of a small molecule, not a peptide, and it does not convert into an oral human dose.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors ERR-alpha, beta and gamma, developed as a chemical tool to activate an exercise-like transcriptional programme without exercise. It is a small molecule, not a peptide, despite being sold through peptide vendors. The rodent work is genuinely interesting and internally consistent, and the compound is the subject of active anti-doping method development, which is itself a signal about how it is being used. Its literature runs to roughly ten indexed papers, all preclinical or analytical. Animal dosing is not converted into a human equivalent anywhere on this page.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-09-05 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — exercise endurance and muscle fibre type in micePreclinical · Preclinical rodent pharmacology, with pharmacokinetics | Three-month-old male C57BL/6J mice, 8-10 per group | 50 mg/kg twice daily; 25 mg/kg in one endurance cohort; 30 mg/kg as a single dose for pharmacokinetics | Intraperitoneal | Twice daily | 7, 10, 14, 15 or 28 days depending on the experiment | Increased type IIa oxidative fibres, enhanced treadmill endurance, and induction of an ERR-alpha-dependent acute aerobic exercise gene programme. No overt toxicity over 10 days at 50 mg/kg twice daily. | Synthetic ERR alpha/beta/gamma Agonist Induces an ERR alpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023. |
| Preclinical — obesity and metabolic syndrome modelsPreclinical · Preclinical | Diet-induced obese and ob/ob mice | Not stated in the report; administered per the dosing established in the originating pharmacology study | Intraperitoneal | — | — | Increased energy expenditure and fatty acid oxidation, decreased fat mass, improved insulin sensitivity | A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024. |
| Preclinical — heart failure modelPreclinical · Preclinical | Rodent heart failure model | Not stated in the report; pan-ERR agonist dosing per the originating pharmacology study | Intraperitoneal | — | — | Improved cardiac fatty acid metabolism and mitochondrial function | Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024. |
Where sources disagree
- SLU-PP-332 is sold as an oral exercise mimetic with milligram daily protocols. Every published in vivo study injected it intraperitoneally in mice. No human study, no registered trial and no oral human dosing exists, and no primary source for those protocols could be identified.
- The compound's own developers went on to publish SLU-PP-915 specifically as an orally active ERR agonist that enhances aerobic exercise capacity. Developing an oral successor is a direct indication that SLU-PP-332 itself is not well suited to the oral route it is generally sold for.
- The mouse dose of 50 mg/kg twice daily is sometimes scaled by body weight into a human figure. Allometric conversion of a rodent intraperitoneal dose to a human oral dose is not valid without pharmacokinetic data in humans, of which there is none, and this site does not publish such a conversion.
Handling & administration
- Reconstitution Guide
- N/A (capsule)
- Concentration Example
- N/A
- Timing Notes
- Morning
- Expected Onset
- Weeks
Sequence & molecular data
| Molecular formula | C18H14N2O2 |
|---|---|
| Molecular weight | 467.5 g/mol |
| CAS number | 303760-60-3 |
| Half-life | Not established |
| Appearance | White powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 5338394 |
| ChEMBL | CHEMBL4208749 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, orphan nuclear receptors that act as transcriptional regulators of oxidative metabolism. Activating them increases expression of genes governing mitochondrial biogenesis, fatty-acid oxidation and oxidative phosphorylation, producing in rodents a transcriptional pattern resembling the adaptation to endurance exercise, together with increased energy expenditure. It is a small molecule rather than a peptide and is not approved for any use; the published work is preclinical, with no human pharmacokinetic or safety data.
Origin
Synthetic small-molecule ERR agonist.
Targets
Studies
- [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling
- Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Regulatory & research status
SLU-PP-332 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
SLU-PP-332 side effects
SLU-PP-332 has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- No established human safety
Contraindications
- Hormone-sensitive cancers
Stacking
Common stacking partners
Combinations that include SLU-PP-332, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
SLU-PP-332: frequently asked questions
What is SLU-PP-332?
Pan-estrogen-related-receptor agonist studied as an exercise mimetic in mice (2023). Not a peptide and not FDA-approved.
How does SLU-PP-332 work?
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, orphan nuclear receptors that act as transcriptional regulators of oxidative metabolism. Activating them increases expression of genes governing mitochondrial biogenesis, fatty-acid oxidation and oxidative phosphorylation, producing in rodents a transcriptional pattern resembling the adaptation to endurance exercise, together with increased energy expenditure.
Is SLU-PP-332 FDA approved?
No. SLU-PP-332 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to SLU-PP-332?
Compounds most often compared with SLU-PP-332 include 5-Amino-1MQ, BAM15, AICAR and Tesofensine. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications] — Rev Med Chil, 2026External reference
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — Int J Biol Macromol, 2026External reference
- Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes — Drug Test Anal, 2026External reference
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — Rapid Commun Mass Spectrom, 2026External reference
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome — J Pharmacol Exp Ther, 2024External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 6, 2026 · Version 2
This SLU-PP-332 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track SLU-PP-332 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →